Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus docetaxel in relapsed head and neck carcinoma
2005-005017-38Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Objective response rate. Started Jun 2006; status: completed.
02
Drugs
cetuximabdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2005-005017-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005017-38.